Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Net Margin (2016 - 2025)

Historic Net Margin for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to 18.08%.

  • Theravance Biopharma's Net Margin rose 933600.0% to 18.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 27.15%, marking a year-over-year increase of 1053300.0%. This contributed to the annual value of 99.39% for FY2024, which is 32800.0% down from last year.
  • As of Q3 2025, Theravance Biopharma's Net Margin stood at 18.08%, which was up 933600.0% from 209.33% recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Net Margin ranged from a high of 7445.92% in Q3 2022 and a low of 212.04% during Q1 2023
  • Its 5-year average for Net Margin is 423.61%, with a median of 18.08% in 2025.
  • Its Net Margin has fluctuated over the past 5 years, first surged by 72897700bps in 2022, then crashed by -75029500bps in 2023.
  • Over the past 5 years, Theravance Biopharma's Net Margin (Quarter) stood at 172.49% in 2021, then plummeted by -85bps to 26.58% in 2022, then plummeted by -282bps to 48.45% in 2023, then plummeted by -154bps to 123.17% in 2024, then soared by 115bps to 18.08% in 2025.
  • Its Net Margin stands at 18.08% for Q3 2025, versus 209.33% for Q2 2025 and 87.98% for Q1 2025.